Novogene Co

Novogene Co Treasury Stock

The Treasury Stock of Novogene Co (688315.SS) as of Oct 31, 2026 is 1.11 B CNY. In the previous year, Treasury Stock was 1.24 B CNY — a change of -10.83% (lower).

Treasury Stock

1.11 BCNY

YoY

-10.83%

Last updated:

Treasury Stock of Novogene Co is 2024 1.11 B CNY. Treasury Stock of Novogene Co was 2023 1.24 B CNY. It decreases by -10.83% lower compared to the previous year.

The Novogene Co Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2017
441.88 M CNY
Jan 1, 2018
449.37 M CNY
Jan 1, 2019
431.89 M CNY
Jan 1, 2020
431.89 M CNY
Jan 1, 2021
888.84 M CNY
Jan 1, 2022
909.46 M CNY
Jan 1, 2023
1.24 B CNY
Jan 1, 2024
1.11 B CNY
The Novogene Co Treasury Stock history
YEARTreasury StockYoY
1.11 BCNY-10.83%
1.24 BCNY+36.57%
909.46 MCNY+2.32%
888.84 MCNY+105.80%
431.89 MCNY0.00%
431.89 MCNY-3.89%
449.37 MCNY+1.70%
441.88 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novogene Co Stock analysis

What does Novogene Co do? Novogene Co., Ltd. generates revenue through genomic services and solutions, primarily utilizing high-throughput sequencing and bioinformatics analysis technologies. The company offers life science basic research services, medical research and technical services, and database-building sequencing platform services, targeting both domestic and international markets. Key products include gene mutation detection kits, coronavirus disease nucleic acid test services, and DA8600 sequencers, which are sold to research institutions, medical facilities, and clinical applications. The firm's technology-driven approach enables it to provide multi-level scientific and research technical services across life science and medical fields. Novogene's revenue streams are anchored in its sequencing platforms and equipment, with the DA8600 sequencers representing a significant product line. The company develops and sells genetic testing medical equipment, leveraging its expertise in gene sequencing. Its services are tailored for life science basic research, medical and clinical applications, and database construction, serving a diverse clientele including research organizations and healthcare providers. The firm's focus on multi-omics research technology enhances its ability to deliver comprehensive solutions. The business model integrates high-throughput sequencing technology with bioinformatics analysis to create scalable services. Novogene's offerings span from basic research support to clinical diagnostic tools, with gene mutation detection kits and coronavirus disease nucleic acid test services catering to specific market needs. The company's domestic and overseas market presence ensures broad client reach, while its independent development of sequencing equipment like the DA8600 sequencers drives product-based revenue. This dual focus on services and equipment positions Novogene as a key player in genomic technology solutions. Novogene Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novogene Co stock

Treasury Stock of Novogene Co is 1.11 B CNY in 2024.

Treasury Stock of Novogene Co changed from 1.24 B CNY to 1.11 B CNY, representing a -10.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock Novogene Co since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's Novogene Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Novogene Co

All Key Metrics — Novogene Co